NASDAQ·Biological Products, (No Diagnostic Substances)
LENZ
LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc. (ticker: LENZ) is an NASDAQ-listed biological products, (no diagnostic substances) company. DredgeCap's structured extraction of LENZ's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. LENZ reported $1.90M in revenue and -$41.49M for the period ending 2026-03-31, with operating cash flow of -$33.58M. Cash and equivalents stood at $24.77M (up 7.5% year-over-year). Total assets of $272.54M exceed total liabilities of $26.04M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
LENZ SEC Filings
Full cached SEC EDGAR filing history for LENZ, grouped by form type and sorted newest-first within each group. 0 filings across 0 form types.
Filings sourced verbatim from SEC EDGAR submissions metadata. “Structured” links route to DredgeCap's per-filing renderer (XBRL-backed financials + cited highlights) when available; the EDGAR link always points to the canonical accession index on sec.gov.